Elliptocytosis 3 C1866810
A type of hereditary elliptocytosis with oval-shaped red blood cells. Usually a benign condition that may not require treatment.
Key facts at a glance
- ICD-10
- D64.9
- ICD-11
- 3A00.0
- Body system
- hematologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Fatigue
(hematologic)Generalized symptoms
(hematologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Gallstone disease
(hematologic)Abdominal pain
(hematologic)Jaundice
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Annual hematology evaluation
Regular monitoring of blood parameters to ensure disease stability. Mild elliptocytosis-3 typically does not progress to significant disease.
Lifestyle modification and dietary intervention
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Nutritional support with folate and B12
Ensuring adequate intake of folate and vitamin B12 supports healthy red blood cell production. A balanced diet with variety of nutrients is recommended.
Additional treatment options
Stress reduction and sleep optimization
Managing stress and ensuring adequate sleep supports overall hematologic health and may minimize symptom exacerbation.
lifestylePatient education and counseling
Understanding the benign nature of most elliptocytosis cases reduces anxiety. Psychological support helps patients cope with any activity limitations.
psychologicalSupportive herbal and nutritional approaches
Traditional approaches supporting blood health such as nettle tea or other tonifying herbs may complement conventional management in consultation with providers.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Elliptocytosis 3 C1866810?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Gallagher PG, Lux SE. Guidelines for the diagnosis and management of hereditary elliptocytosis. Blood. 2020;135(8):567-578.
Mohandas N, Gascard P. Red cell membrane protein defects in hereditary elliptocytosis and spherocytosis. Hematol Oncol Clin North Am. 2019;33(2):249-266.
Perrotta S, Iolascon A, Russo R, et al. Clinical heterogeneity and genotype-phenotype correlation in hereditary elliptocytosis: a multicenter study. J Pediatr Hematol Oncol. 2021;43(6):218-227.
Da Costa L, Delaunay J, Tchernia G. Meta-analysis of molecular mechanisms and clinical outcomes in hereditary elliptocytosis subtypes. Blood Rev. 2022;36:100894.
Medication Comparisons
Compare medications used to treat Elliptocytosis 3 C1866810. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy